



Role of Functional Echocardiography in NICU

Nim Subhedar

Neonatologist, Liverpool Women's Hospital





Personalised haemodynamic management



All preterm infants same treatment protocol
All preterm newbons same dose/kg bodyweight



- Treatment is stratified to specific patient characteristics
- Drug dosing based on gestational age, post-natal age, gender or co-medication

INDIVIDUALIZED NEONATOLOGY



- Treatment specified to the individual infant
- Drug dosing based on genotype, MIPD (model informed precision dosing), continuous effect registration





Potential role of functional echo

- Assessment of hypotension/'shock'
- Hypoxaemic respiratory failure/PPHN
- PDA diagnosis and management
- Management of BPD-PH

When to intervene? What drug to use?

British Association of

How to escalate/wean/stop treatment?

REVIEW ARTICLE OPEN Introduction to neonatologist-performed echocardiography

Alan M. Groves¹, Yogen Singh², Eugene Dempsey³, Zoltan Molnar⁴, Topun Austin⁵, Afif El-Khuffash^{6,7} and Willem P. de Boode⁸ on behalf of the European Special Interest Group 'Neonatologist Performed Echocardiography' (NPE)

Cardiac ultrasound techniques are increasingly used in the neonatal intensive care unit to guide cardiorespiratory care of the sick newborn. This is the first in a series of eight review articles discussing the current status of "neonatologist-performed echocardiography" (NPE). The aim of this introductory review is to discuss four key elements of NPE. Indications for scanning are summarized to give the neonatologist with echocardiography skills a clear scope of practice. The fundamental physics of ultrasound are explained to allow for image optimization and avoid erroneous conclusions from artifacts. To ensure patient safety during echocardiography recommendations are given to prevent cardiorespiratory instability, hypothermia, infection, and skin lesions. A structured approach to echocardiography, with the same standard views acquired in the same sequence at each scan, is suggested in order to ensure that the neonatologist confirms normal structural anatomy or acquires the necessary images for a pediatric cardiologist to do so when reviewing the scan.

Pediatric Research (2018) 84:S1-S12; https://doi.org/10.1038/s41390-018-0076-y





Check for updates

Case

29 weeks, 990 g PPROM 72h with anhydramnios AN steroids Cord prolapse → Em CS

Delayed cord clamping Intubated 8 mins, surfactant

VG-PS ventilation, requiring high PIP \rightarrow HFOV

Hypotension (BP 37/24) (? volume)

FiO2 1.0 (? PPHN ?iNO)















Well-filled LV

Poor bi-ventricular function

Low LV output (110 ml/kg/min)

Pulmonary hypertension (sPAP ~55)

R to L ductal flow L to R atrial flow <u>Not</u> for volume expansion (no evidence of hypovolaemia)

Inotrope (not vasopressor) \rightarrow low dose adrenaline

<u>Not</u> for iNO (contra-indicated in LV dysfunction)

Re-echo 12 hours later – improved LV function \rightarrow iNO













-1.03

171 HR Soft

RV systolic dysfunction

Optimise pulmonary vasodilation

Milrinone/vasopressin

Start prostin to maximise ductal patency



Hypotension/shock





Neonatal Pulmonary Hypertension



What is the problem?

Measurement of BP and treatment of hypotension is too simplistic an approach

Most neonatal cardiorespiratory disorders have complex underlying haemodynamics

'Blind' treatment according a to pre-specified protocol is illogical and potentially harmful

Population-based management is unlikely to be effective given variation in clinical/physiological phenotype



What does functional echo offer the neonatologist?

Comprehensive echo assessment provides meaningful information about cardiac function and haemodynamics (instead of just relying on BP)

Choice of treatment based on the specific underlying haemodynamic pathophysiology ('precision medicine')

Ability to assess response to treatment and manage appropriately

Potential of improved short-term and long-term outcomes

Standardised assessment in specific conditions (e.g. threshold for PDA treatment; BPD-PH)





Impact of Early Hemodynamic Screening on Extremely Preterm Outcomes in a High-Performance Center

Regan E Giesinger¹, Danielle R Rios¹, Trassanee Chatmethakul^{1,2}, Adrianne R Bischoff¹, Jeremy A Sandgren¹, Alison Cunningham³, Madeline Beauchene³, Amy H Stanford¹, Jonathan M Klein¹, Patrick Ten Eyck⁴, Patrick J McNamara^{1, 5}

Before-and-after study

2 cohorts (2010-2017) vs (2018-2022)

Impact of TNE 'screening' at 12-18h of 22-26w infants



Guidelines for Hemodynamic Screening and Management of Extreme Preterm Neonates

Eligibility Criteria:

- All preterm infants ≤ 26⁺⁶ weeks GA, TnECHO 12-18h postnatal age + notify Hemodynamics
- PDA screen low risk infants 27 29⁺⁶ weeks GA on a weekday between postnatal day 3-7
- *Excluded*: Fetal diagnosis of congenital heart disease

Small PDA or PDA with a low volume shunt	If PDA with mod- high volume shunt	Acute PH	Cardiac dysfunction (LV/RV)	Congenital heart disease
v v v v v v v v v v v v v v v v v v v	\			
Observe	Treat	Treat	Treat	Refer
Repeat TnECHO day	Tylenol 15mg/kg IV	inhaled nitric	Dobutamine at 2.5-5	Consult Pediatric
3-7 or sooner; If	Q6H x 12-16 doses	oxide 5-	mcg/kg/min	Cardiology
low volume shunt		20ppm	first line; alternative	
due to high PVR,			agents as needed	
follow TnECHO Q 1-		, <u> </u>		1
2 days until PVR	Repeat TnECHO	Repeat		1
normal or after	within 12-24h after	TnECHO	Repeat TnECHO	
starting iNO if	at least 12 doses of	6-24h after	6-24h after starting	
needed for HRF	Tylenol	starting iNO	cardiotropic therapy	
	↓			
PDA significance is	Remains significant	Remains signi	ificant If remain	s significant both
determined PDA	Complete 28 total	Indomethacin x	3 doses clinically an	d hemodynamically:
score ≥6 & clinical	Tylenol doses prior	followed by re-e	valuation 🔽 Recommend	definitive closure by
status	to re-evaluation	(indomethacin 1	-2 trials) percut	taneous device





Personalised haemodynamic management



All preterm infants same treatment protocol
All preterm newbons same dose/kg bodyweight



- Treatment is stratified to specific patient characteristics
- Drug dosing based on gestational age, post-natal age, gender or co-medication

INDIVIDUALIZED NEONATOLOGY



- Treatment specified to the individual infant
- Drug dosing based on genotype, MIPD (model informed precision dosing), continuous effect registration



